P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial

• Published in: Lupus science & medicine 2024-03, Vol.11 (Suppl 1), p.A168-A169
• Main Authors: Vollenhoven, Ronald F van, Merola, Joseph F, Dao, Kathryn H, Leszczynski, Piotr, Pike, Marilyn, Pomponi, Samantha, Hobar, Coburn, Colombo, Matthew J, Koti, Ravi, Banerjee, Subhashis, Wegman, Thomas, Morand, Eric
• Format: Article
• Language: English
• Subjects: Lupus; Poster Presentations; Response rates
• ISSN: 2053-8790
• DOI: 10.1136/lupus-2024-el.219

ObjectiveDeucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate-to-severe plaque psoriasis. The 48-week, double-blind, phase 2 PAISLEY trial in patients with active SLE (NCT03252587) met its primary endpoint and all key secondary endpoints at deucravacitinib 3 mg twice-daily (BID) vs placebo. In this post-hoc analysis, response rates over time were evaluated for ≥50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score from baseline in patients with a baseline CLASI score ≥10 (CLASI-50), ≥50% reduction in active (swollen+tender) joint count in patients with ≥6 active joints at baseline (AJC-50), and other key secondary endpoints.MethodsPatients with active SLE receiving standard-of-care were randomized 1:1:1:1 to placebo (n=90), deucravacitinib 3 mg BID (n=91), 6 mg BID (n=93), or 12 mg once-daily (QD) (n=89). Previous reporting from PAISLEY used strict nonresponder imputation criteria with several conditions considered a nonresponse applied after week 20, including not achieving a glucocorticoid dose ≤7.5 mg/day by week 20, resulting in different imputation methods used before vs after week 20. Here, we characterize disease activity improvement in 2 key lupus manifestations, imputing only missing data as nonresponse (M=NR) through week 48 and assessing response rate kinetics using the same imputation method.ResultsPatients receiving deucravacitinib had numerically higher CLASI-50 response rates vs placebo starting at week 4 (placebo, 4.2%; 3 mg BID, 21.7%; 6 mg BID, 8.0%; 12 mg QD, 27.6%) (figure 1A); robust differences were maintained through week 48. Numerical differences in AJC-50 response rates were first observed at week 8 (placebo, 54.7%; 3 mg BID, 69.8%; 6 mg BID, 73.8%; 12 mg QD, 59.7%) and became more notable from week 24 (figure 1B). Differences in responses of both organs were maintained with deucravacitinib beyond week 20, after the protocol-mandated glucocorticoid taper.ConclusionThese data suggest that higher response rates with deucravacitinib vs placebo occur early on for mucocutaneous and somewhat later for musculoskeletal manifestations. Permitted concomitant glucocorticoid use may partially explain the placebo group responses. Robust differences were seen after the glucocorticoid taper, further supporting the efficacy of deucravacitinib.Abstract P165 Figure 1Response rates from weeks 4 to 48 in pa